Plandai biotechnology discusses potential for using phytofare in treating type ii diabetes markets insider r studio data recovery full version

LONDON, UNITED KINGDOM, June 12, 2018 (GLOBE NEWSWIRE) — Plandai Biotechnology, Inc. (OTCQB: PLPL) ("Plandai" or "the Company"), producer of the highly bioavailable Phytofare® catechin complex, today discussed the potential benefits of using highly-bioavailable green tea catechins, like those found in the Company’s proprietary Phytofare® extract, in treating people suffering from Type II diabetes.  Worldwide as of 2013, 382 million people, or 8.3% of the adult population, have diabetes, with Type II Diabetes making up about 90% of the cases. In 2014, the International Diabetes Federation estimated that diabetes resulted in 4.9 million annual deaths.

Data from in vitro and in vivo studies suggest that green tea catechins, in particularly EGCG, may exert anti-obesity effects via several mechanisms including inhibition of adipocyte differentiation and proliferation, reduction of fat absorption, and reductions in fat mass, triglycerides, free fatty acids and total cholesterol.


 The majority of human intervention studies investigating glucose homeostasis further demonstrate improved glucose levels in response to green tea catechins. Human studies have shown anti-obesity, anti-diabetic and cardio-protective properties of green tea catechins (1). Â

Callum Cottrell-Duffield, Chief Operating Officer of Plandai, commented, “Diabetes is now the leading cause of death in South Africa and the rates are only climbing through much of sub-Sahara Africa and the developing world where fat-rich foods have supplanted traditional diets. There is a strong body of scientific research suggesting the effectiveness of green tea catechins in managing obesity, high blood pressure, Type II diabetes and other diet-related diseases. These prior studies, however, concur that green tea catechins are poorly absorbed into the blood stream, rendering them an ineffective primary control therapy. Phytofare®, on the other hand, which has ten-times greater absorption, may very well provide an inexpensive, all-natural solution to these diseases. We want to build on this prior research and show the benefits of Phytofare® in managing glucose levels, with a short-term goal of having a consumer-ready capsule product.”

Plandai Biotechnology, Inc. (OTC Markets: PLPL) develops highly bioavailable, phytonutrient rich extracts which are being utilized to deliver a new family of drugs to safely and affordably treat a multitude of diseases and conditions. Plandai Biotechnology, through its South African subsidiaries, controls every aspect of production, from growing specific raw materials such as green tea on its farms to producing its proprietary Phytofare extract, allowing the Company to guarantee the continuity of supply as well as quality control throughout the entire process. The manufacturing facility has also been engineered for citrus fruits and the recovery of limonoids. Targeted industries for the Company’s products include animal husbandry, dietary supplements, diabetes and cannabis. Plandai Biotechnology is headquartered in London, United Kingdom. For more information, please visit: http://www.plandaibiotech.comÂ

This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. All statements other than statements of historical facts included in this press release are forward-looking statements. These statements relate to future events or to the Company’s future financial performance, and involve known and unknown risks, uncertainties and other factors that may cause actual results, levels of activity, performance or achievements to be materially different from any future results, levels of activity, performance or achievements expressed or implied by these forward-looking statements. Investors should not place any undue reliance on forward-looking statements since they involve known and unknown, uncertainties and other factors which are, in some cases, beyond the Company’s control which could, and likely will, materially affect actual results, levels of activity, performance or achievements. Any forward-looking statement reflects the Company’s current views with respect to future events and is subject to these and other risks, uncertainties and assumptions relating to operations, results of operations, growth strategy and liquidity. Such risks, uncertainties and other factors, which could impact the Company and the forward-looking statements contained herein are included in the Company’s filings with the OTC Markets. The Company assumes no obligation to publicly update or revise these forward-looking statements for any reason, or to update the reasons actual results could differ materially from those anticipated in these forward-looking statements, even if new information becomes available in the future.

banner